Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:CORV

Correvio Pharma (CORV) Stock Price, News & Analysis

→ What President Biden's new law means for investors (From Stansberry Research) (Ad)
Free CORV Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.42
▼
$0.42
50-Day Range
$0.39
▼
$0.42
52-Week Range
$0.21
▼
$2.79
Volume
N/A
Average Volume
5.35 million shs
Market Capitalization
$27.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Correvio Pharma

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

CORV Stock News Headlines

May 16, 2024 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
May 15, 2024 | morningstar.com
Big Pharma Split Corp Class A
May 13, 2024 | msn.com
Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets
May 13, 2024 | markets.businessinsider.com
Positive Outlook for Verona Pharma with Strong Financial Position and Anticipated Drug Approval
May 11, 2024 | businesswire.com
Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure
May 10, 2024 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
May 9, 2024 | msn.com
Traws Pharma Advances COVID-19 Treatment into First Human Trials
May 9, 2024 | bizjournals.com
Raleigh pharma secures $650M to be ready for growth surge
May 7, 2024 | finance.yahoo.com
Nutra Pharma Corp. (NPHC)
May 7, 2024 | markets.businessinsider.com
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
April 19, 2024 | wsj.com
Protect Pharmaceutical Corp.
April 16, 2024 | morningstar.com
Stella Pharma Corp Ordinary Shares 4888
April 9, 2024 | msn.com
Natco Pharma gets USFDA warning letter for Kothur plant
March 29, 2024 | markets.businessinsider.com
Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns
March 19, 2024 | washingtonpost.com
Corvus: Q4 Earnings Snapshot
March 15, 2024 | bizjournals.com
'This is a sleeping giant:' UC seals licensing deal with TRPV Pharmaceuticals for new heart failure drug
March 13, 2024 | marketwatch.com
Corbus Pharmaceuticals Stock Climbs on Narrower-Than-Expected 4Q Loss
March 1, 2024 | msn.com
Garware Fulflex India acquires Avcor Health Care Products to strengthen its medical product portfolio
February 17, 2024 | wsj.com
Chong Kun Dang Pharmaceutical Corp.
February 12, 2024 | finance.yahoo.com
Silver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As President
January 14, 2024 | morningstar.com
Chong Kun Dang Pharmaceutical Corp
December 12, 2023 | seekingalpha.com
Corvus Pharmaceuticals: Ahead Of The Clinical-Stage Curve
December 7, 2023 | bizjournals.com
AbbVie is acquiring two local biotechs — but won't detail its plans for them
December 7, 2023 | msn.com
AbbVie – Cerevel M&A deal lifts Reviva, Karuna
November 30, 2023 | benzinga.com
Scout Clinical secures preferred supplier status with Top 5 Pharma Leader
See More Headlines

Company Calendar

Last Earnings
3/30/2020
Today
5/20/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CORV
CUSIP
N/A
CIK
N/A
Web
www.correvio.com
Phone
604-677-6905
Fax
N/A
Employees
133
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,180,000.00
Net Margins
-107.81%
Pretax Margin
N/A
Return on Equity
-2,128.82%
Return on Assets
-58.56%

Debt

Debt-to-Equity Ratio
22.54
Current Ratio
1.07
Quick Ratio
0.95

Sales & Book Value

Annual Sales
$32.63 million
Price / Sales
0.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
-21.00

Miscellaneous

Outstanding Shares
66,191,000
Free Float
N/A
Market Cap
$27.80 million
Optionable
Optionable
Beta
0.08

Key Executives

  • Dr. Mark H. N. Corrigan (Age 62)
    CEO & Director
  • Mr. Justin A. Renz CPA (Age 48)
    MST, M.S.T., MBA, CFO & Pres
  • Ms. Sheila M. Grant
    Chief Operating Officer
  • Mr. David D. McMasters (Age 61)
    Chief Compliance Officer & Gen. Counsel
  • Mr. Hugues Sachot
    Chief Commercial Officer

Key Competitors

View All Competitors

CORV Stock Analysis - Frequently Asked Questions

How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) issued its quarterly earnings data on Monday, March, 30th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The firm had revenue of $11.33 million for the quarter, compared to analyst estimates of $11.52 million. Correvio Pharma had a negative trailing twelve-month return on equity of 2,128.82% and a negative net margin of 107.81%.

What other stocks do shareholders of Correvio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Correvio Pharma investors own include Inovio Pharmaceuticals (INO), Outlook Therapeutics (OTLK), SCYNEXIS (SCYX), Heat Biologics (HTBX), Actinium Pharmaceuticals (ATNM), Acasti Pharma (ACST), Biocept (BIOC), Vaxart (VXRT), Co-Diagnostics (CODX).

This page (NASDAQ:CORV) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Elon to Transform U.S. Economy?
Porter & Company
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
"The Biggest Drug Ever" Is Coming
Behind the Markets
Most important medical advance in 100 years
The Oxford Club
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star